What is the clinical evidence from this study?

Study design: Review. Population: Atherosclerotic coronary disease and restenosis. Intervention: Percutaneous transluminal coronary angioplasty.

What does this research mean for the field?

Despite an increased understanding of its molecular mechanisms involving neointimal hyperplasia, restenosis after coronary angioplasty currently lacks effective technological or pharmacological treatments, though gene therapy presents a potential future solution. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To address the issue of restenosis following successful coronary angioplasty procedures.

June 29, 2026European Heart Journal

Restenosis after coronary angioplasty

View Full Paper

Ask AI

Bookmark

Key result

Post-angioplasty restenosis remains frequent from neointimal hyperplasia, with no effective treatment currently available.

Population

Patients with atherosclerotic coronary disease treated with percutaneous transluminal coronary angioplasty

Design

Review

Authors

MHM. HamonCentre Hospitalier Universitaire de Caen Normandie CBChristophe BautersInterventional Cardiology EME McFaddenUniversity College Cork

Discussion

Member takes

Implication

Restenosis remains a major unresolved complication of coronary angioplasty, highlighting the need for novel approaches such as gene therapy.

Key Points

To address the issue of restenosis following successful coronary angioplasty procedures.
Review of histological observations and animal studies on restenosis mechanisms.
Assessment of technological and pharmacological interventions against restenosis rates.
Restenosis is primarily due to smooth muscle cell proliferation and extracellular matrix synthesis.
Recent technological advances have not significantly reduced restenosis rates.
Gene therapy shows promise based on initial results in experimental models.

Structured PICO

Population

Patients with atherosclerotic coronary disease treated with percutaneous transluminal coronary angioplasty

Restenosis remains a major unresolved complication of coronary angioplasty, highlighting the need for novel approaches such as gene therapy.

Cite This Study

Hamon et al. (1995) conducted a review in Atherosclerotic coronary disease and restenosis. Percutaneous transluminal coronary angioplasty was evaluated. Restenosis after coronary angioplasty remains a frequent complication characterized by neointimal hyperplasia, with no effective treatment currently available despite technological improvements.

synapsesocial.com/papers/6a41e43dd8bc5ceb756acc14 https://doi.org/10.1093/eurheartj/16.suppl_i.33

View Full Paper

Ask AI

Bookmark

Implication

Restenosis remains a major unresolved complication of coronary angioplasty, highlighting the need for novel approaches such as gene therapy.